Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study
Séverine Vermeire(KU Leuven), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Julien Santo(Abivax (France)), Parambir S. Dulai(Northwestern Medicine), Didier Scherrer(Abivax (France)), Britta Siegmund(Humboldt-Universität zu Berlin), Paul Gineste(Abivax (France)), Tadakazu Hisamatsu(Kyorin University), Josianne Nitcheu(Abivax (France)), Herbert Tilg(Innsbruck Medical University), Silvio Danese(IRCCS Ospedale San Raffaele), Christopher J. Rabbat(Abivax (France)), Aurelien Flatres(Abivax (France)), Laurent Peyrin-Biroulet(Inserm), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai)
Cited by 10
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k